[Raynaud phenomenon and scleroderma].
The Raynaud phenomenon occurs in 90-100% of patients with systemic scleroderma. It is caused by dysregulation of the vascular tone between vasoconstrictive and vasodilatory influences. Early damage to the vascular endothelium and the activation of platelets lead to the release of vasoactive substances. Structural and function impairment of the perivascular neural fibers contributes to the vasospasm. New vasodilatory treatment strategies, e.g. infusions with calcitonin gene-related peptides, could be useful in the control of vasospasm in the peripheral extremities as well as internal organs in systemic scleroderma.
Haustein
U F
UF
Klinik und Poliklinik für Hautkrankheiten der Universität, Leipzig.
D015740:Calcitonin Gene-Related Peptide / Q000008:administration & dosage; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology; D011928:Raynaud Disease / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000008:administration & dosage
D014665:Vasodilator Agents; D015740:Calcitonin Gene-Related Peptide
Raynaud-Phänomen und Sklerodermie.